Nebenwirkungen · Stoboclo
Stoboclo 60 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 7
HOS-151772 · Präparat HOS-100617
Hypocalcaemia In two phase III placebo-controlled clinical trials in postmenopausal women with osteoporosis, approximately 0.05% (2 out of 4 050) of patients had declines of serum calcium levels (less than 1.88 mmol/L) following denosumab administration. Declines of serum calcium levels (less than 1.88 mmol/L) were not reported in either the two phase III placebo-controlled clinical trials in patients receiving hormone ablation or the phase III placebo-controlled clinical trial in men with osteoporosis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-14T10:26:00Z · SHA-256 f419b328c2016d74581bc8efd27c9862fbb391b06329b5486357d6e8e8e74b75 · Passage 7ab26ce8b11450f19830e1faf8c2ea6594492dd7875f29370de52d429b1ad00c · Zeichen 3684–4192 im Abschnitt